Semen and serum pharmacokinetics of zidovudine and zidovudine-glucuronide in men with HIV-1 infection

被引:21
作者
Anderson, PL
Noormohamed, SE
Henry, K
Brundage, RC
Balfour, HH
Fletcher, CV
机构
[1] Univ Minnesota, Acad Hlth Sci Ctr, Dept Expt & Clin Pharmacol, Minneapolis, MN 55455 USA
[2] Univ Minnesota, Acad Hlth Sci Ctr, Dept Med, Minneapolis, MN 55455 USA
[3] Univ Minnesota, Acad Hlth Sci Ctr, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA
[4] Univ Minnesota, Acad Hlth Sci Ctr, Dept Pediat, Minneapolis, MN 55455 USA
来源
PHARMACOTHERAPY | 2000年 / 20卷 / 08期
关键词
D O I
10.1592/phco.20.11.917.35263
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Study Objective. To characterize the concentration-time profiles of zidovudine and zidovudine-glucuronide in semen and serum of men infected with the human immunodeficiency-1 virus (HIV-1). Design. Open-label observational study. Setting. University-affiliated teaching hospital and research center. Patients. Four asymptomatic HIV-1-infected men. Interventions. Zidovudine administration was followed by an 8-hour intensive pharmacokinetic study on day 1. Over the next 8 days, a dose administration and timed single-sample strategy was employed to determine serum and semen concentration time profiles simultaneously. Measurements and Main Results. Zidovudine and zidovudine-glucuronide concentrations were uniformly higher in semen than in serum except at 1 hour after the dose. The median area under the curve ratio (semen AUC(0-48):serum AUC(0-infinity)) was 3.31 for zidovudine and 15.04 for zidovudine-glucuronide. Conclusion. Zidovudine and zidovudine-glucuronide reach high levels in seminal plasma relative to serum. The virologic, pharmacodynamic, and public health implications of distribution to this compartment require further study.
引用
收藏
页码:917 / 922
页数:6
相关论文
共 36 条
[1]   EFFECTS OF DISEASE STAGE AND ZIDOVUDINE THERAPY ON THE DETECTION OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 IN SEMEN [J].
ANDERSON, DJ ;
OBRIEN, TR ;
POLITCH, JA ;
MARTINEZ, A ;
SEAGE, GR ;
PADIAN, N ;
HORSBURGH, CR ;
MAYER, KH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 267 (20) :2769-2774
[2]   HIV-1 in semen: an isolated virus reservoir [J].
Byrn, RA ;
Zhang, DZ ;
Eyre, R ;
McGowan, K ;
Kiessling, AA .
LANCET, 1997, 350 (9085) :1141-1141
[3]   HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy [J].
Deeks, SG ;
Hecht, FM ;
Swanson, M ;
Elbeik, T ;
Loftus, R ;
Cohen, PT ;
Grant, RM .
AIDS, 1999, 13 (06) :F35-F43
[4]  
Department of Health and Human Services, 2000, GUID US ANT AG HIV I
[5]   A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE EFFECT OF CHRONICALLY ADMINISTERED ORAL ACYCLOVIR ON SPERM PRODUCTION IN MEN WITH FREQUENTLY RECURRENT GENITAL HERPES [J].
DOUGLAS, JM ;
DAVIS, LG ;
REMINGTON, ML ;
PAULSEN, CA ;
PERRIN, EB ;
GOODMAN, P ;
CONNER, JD ;
KING, D ;
COREY, L .
JOURNAL OF INFECTIOUS DISEASES, 1988, 157 (03) :588-593
[6]   BRIEF REPORT - PRIMARY INFECTION WITH ZIDOVUDINE-RESISTANT HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 [J].
ERICE, A ;
MAYERS, DL ;
STRIKE, DG ;
SANNERUD, KJ ;
MCCUTCHAN, FE ;
HENRY, K ;
BALFOUR, HH .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (16) :1163-1165
[7]   Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission [J].
Eron, JJ ;
Vernazza, PL ;
Johnston, DM ;
Seillier-Moiseiwitsch, S ;
Alcorn, TM ;
Fiscus, SA ;
Cohen, MS .
AIDS, 1998, 12 (15) :F181-F189
[8]   Concentration-controlled zidovudine therapy [J].
Fletcher, CV ;
Acosta, EP ;
Henry, K ;
Page, LM ;
Gross, CR ;
Kawle, SP ;
Remmel, RP ;
Erice, A ;
Balfour, HH .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (03) :331-338
[9]  
FLETCHER CV, 1995, PHARMACOTHERAPY, V15, P701
[10]  
FLETCHER CV, 1992, PHARMACOTHERAPY, V12, P429